Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.57 |
| ▸ | FABP1 | P07148 | 1/20 | 0.55 |
| ▸ | FABP6 | P51161 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | FERMT2 | Q96AC1 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | FDPS | P14324 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7518301 | 0.98 | CYP1A2 (0.59) | CYP1A2CYP2C19CXCR4FABP1FABP6 | |
| Hydrochloric Acid SCHEMBL5270311 | 0.98 | CYP1A2 (0.59) | CYP1A2CYP2C19CXCR4FABP1FABP6 | |
| SCHEMBL8085273 | 0.89 | CYP1A2 (0.51) | CYP1A2CYP2C19CXCR4FABP1FABP6 | |
| SCHEMBL1831590 | 0.88 | CYP1A2 (0.58) | CYP1A2CYP2C19CXCR4FABP1FABP6 | |
| SCHEMBL3265804 | 0.87 | CYP1A2 (0.70) | CYP1A2CYP2C19CXCR4FABP1FABP6 | |
| Hydrochloric Acid SCHEMBL6300353 | 0.86 | CYP1A2 (0.56) | CYP1A2CYP2C19CXCR4FABP1FABP6 | |
| SCHEMBL1831059 | 0.86 | CYP1A2 (0.56) | CYP1A2CYP2C19CXCR4FABP1FABP6 | |
| SCHEMBL10887684 | 0.85 | CYP1A2 (0.54) | CYP1A2CYP2C19CXCR4FABP1FABP6 | |
| SCHEMBL4715114 | 0.85 | CYP1A2 (0.54) | CYP1A2CYP2C19CXCR4FABP1FABP6 | |
| Hydrochloric Acid SCHEMBL6302628 | 0.85 | CYP1A2 (0.54) | CYP1A2CYP2C19CXCR4FABP1FABP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 410 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112876688-B | Preparation method of nano micelle suitable for tandem catalysis | 浙江理工大学 | 2022-10-28 | — | — | CN | claimed |
| EP-3246027-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF CANCER | GlaxoSmithKline LLC (US) | 2017-11-22 | — | — | EP | claimed |
| EP-2646020-B1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2016-09-21 | — | — | EP | claimed |
| US-9402836-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2016-08-02 | — | — | US | claimed |
| US-20150313887-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2015-11-05 | — | — | US | claimed |
| US-8975291-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2015-03-10 | — | — | US | claimed |
| EP-2566328-B1 | INDAZOLES | GLAXOSMITHKLINE LLC (US) | 2015-03-04 | — | — | EP | claimed |
| EP-2566479-B1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC (US) | 2014-12-24 | — | — | EP | claimed |
| EP-2773754-A1 | METHOD OF TREATMENT | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2014-09-10 | — | — | EP | claimed |
| CN-104039956-A | Method of treatment | GLAXOSMITHKLINE IP NO 2 LTD | 2014-09-10 | — | — | CN | claimed |
| WO-2011140325-A1 | INDAZOLES | GLAXOSMITHKLINE LLC (US) | 2011-11-10 | — | — | WO | claimed |
| WO-2011140324-A1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2011-11-10 | — | — | WO | claimed |
| US-20090264411-A1 | FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2009-10-22 | — | — | US | claimed |
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2009-05-21 | — | — | US | claimed |
| EP-1615921-B1 | PYRIDO 2,3-D PYRIMIDIN-7-CARBOXYLIC ACID DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | HOFFMANN LA ROCHE (CH) | 2009-03-18 | — | — | EP | claimed |
| US-7163941-B2 | Pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2007-01-16 | — | — | US | claimed |
| EP-1615921-A2 | PYRIDO 2,3-D PYRIMIDIN-7-CARBOXYLIC ACID DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-18 | — | — | EP | claimed |
| US-20050130984-A1 | Pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents | F. HOFFMANN-LA ROCHE AG (DE) | 2005-06-16 | — | — | US | claimed |
| WO-2004085436-A2 | PYRIDO[2,3-D]PYRIMIDIN-7-CARBOXYLIC ACID DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-07 | — | — | WO | claimed |
| WO-2001064680-A1 | MYT1 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-09-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130984-A1 | Pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents | LCK, TYRO3, ABL1 | CYP1A2 830/4885CYP2C19 322/4885CXCR4 2241/4885 |
| US-20090264411-A1 | FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS | MAPK15, MOK, MAPK14 | CYP1A2 2113/4885CYP2C19 963/4885CXCR4 2392/4885 |
| US-20150313887-A1 | INDOLES | IDO1, IDO2, INMT | CYP1A2 53/4885CYP2C19 106/4885CXCR4 3598/4885 |
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | WNT3A, WNT1, WNT3 | CYP1A2 413/4885CYP2C19 1078/4885CXCR4 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.